Document:

TherapeuticsMD, Inc. 10-K

Exhibit
10.14

 

 

 

AMENDMENT
TO WARRANT

 

 

This
Amendment to Warrant (this “Amendment”) is dated as of February 18, 2021 by and between Robert G. Finizio
(“Holder”) and TherapeuticsMD, Inc. (“Company”).

 

Recitals

 

WHEREAS,
in connection with the guaranty by Holder of a line of credit issued by 1st United Bank to vitaMedMD, LLC, a Delaware
limited liability company and wholly owned subsidiary of the Company on March 6, 2011, Company issued to Holder that certain Warrant
No. 1 dated as of October 4, 2011 granting Holder the right to purchase 204,571 shares of common stock, $0.001 par value per share,
of the Company (“Shares”) at a per Share price of $0.2444 (the “Warrant”).

 

WHEREAS,
pursuant to Section 11 of the Warrant, neither the Warrant nor any term thereof may be changed, waived, discharged or terminated
without the prior written consent of Holder and the Company.

WHEREAS,
Company and Holder wish to amend the Warrant in order to allow for a cashless exercise of the Warrant.

NOW,
THEREFORE, Company and Holder agree as follows:

1.       The
Warrant is hereby amended to add Sections 2(e) and 2(f), to read in their entirety as follows:

(e)       In
lieu of, or in addition to, exercising this Warrant as specified in subsection (a) above, Holder may from time to time convert
this Warrant, in whole or in part, into a number of Shares determined by dividing (a) the aggregate fair market value of the Shares
or other securities otherwise issuable upon exercise of this Warrant minus the aggregate Purchase Price of such Shares by (b)
the fair market value of one Share. The fair market value of the Shares shall be determined pursuant to subsection (f) of this
Section.

(f)       If
the Shares are traded regularly in a public market, the fair market value of the Shares shall be the closing price of the Shares
reported for the business day immediately before Holder delivers its completed Exercise Agreement to the Company. If the Shares
are not regularly traded in a public market, the Board of Directors of the Company shall determine fair market value in its reasonable
good faith judgment.

2.       Except
as amended hereby, the Warrant remains in full force and effect. This Amendment may be executed in two or more counterparts, each
of which shall be deemed an original, and both of which shall constitute one instrument.

	THERAPEUTICSMD,
                                         INC.

         

        By:_/s/
        James C. D’Arecca_________________

        James
        C. D’Arecca

        Chief
        Financial Officer
	ROBERT
                                         G. FINIZIO

         

        By:__/s/
        Robert G. Finizio_________________TherapeuticsMD, Inc. 10-K

Exhibit
10.16

 

AMENDMENT TO WARRANT

 

 

This Amendment to Warrant
(this “Amendment”) is dated as of February 20, 2021 by and between John C.K. Milligan, IV (“Holder”)
and TherapeuticsMD, Inc. (“Company”).

 

Recitals

 

WHEREAS, in connection
with the guaranty by Holder of a line of credit issued by 1st United Bank to vitaMedMD, LLC, a Delaware limited liability
company and wholly owned subsidiary of the Company on March 6, 2011, Company issued to Holder that certain Warrant No. 2 dated
as of October 4, 2011 granting Holder the right to purchase 204,571 shares of common stock, $0.001 par value per share, of the
Company (“Shares”) at a per Share price of $0.2444 (the “Warrant”).

 

WHEREAS, pursuant
to Section 11 of the Warrant, neither the Warrant nor any term thereof may be changed, waived, discharged or terminated without
the prior written consent of Holder and the Company.

WHEREAS, Company
and Holder wish to amend the Warrant in order to allow for a cashless exercise of the Warrant.

NOW, THEREFORE,
Company and Holder agree as follows:

1.       The
Warrant is hereby amended to add Sections 2(e) and 2(f), to read in their entirety as follows:

(e)       In
lieu of, or in addition to, exercising this Warrant as specified in subsection (a) above, Holder may from time to time convert
this Warrant, in whole or in part, into a number of Shares determined by dividing (a) the aggregate fair market value of the Shares
or other securities otherwise issuable upon exercise of this Warrant minus the aggregate Purchase Price of such Shares by (b) the
fair market value of one Share. The fair market value of the Shares shall be determined pursuant to subsection (f) of this Section.

(f)       If
the Shares are traded regularly in a public market, the fair market value of the Shares shall be the closing price of the Shares
reported for the business day immediately before Holder delivers its completed Exercise Agreement to the Company. If the Shares
are not regularly traded in a public market, the Board of Directors of the Company shall determine fair market value in its reasonable
good faith judgment.

2.       Except
as amended hereby, the Warrant remains in full force and effect. This Amendment may be executed in two or more counterparts, each
of which shall be deemed an original, and both of which shall constitute one instrument.

	
        THERAPEUTICSMD, INC.

         

        By:_/s/ James C. D’Arecca_________________

        James C. D’Arecca

        Chief Financial
        Officer
	
        JOHN C.K. MILLIGAN, IV

         

        By: John C.K. Milligan, IVTherapeuticsMD, Inc. 10-K

 

Exhibit
10.24 

 

AMENDMENT
NO. 7

TO FINANCING AGREEMENT

 

AMENDMENT
NO. 7 TO FINANCING AGREEMENT, dated as of January 13, 2021 (this “Amendment”), to the Financing Agreement,
dated as of April 24, 2019 (as amended, restated, supplemented or otherwise modified from time to time, the “Financing
Agreement”), by and among THERAPEUTICSMD, INC., a Nevada corporation (“Company” or “Borrower”),
certain Subsidiaries of Borrower, as Guarantors, the Lenders from time to time party thereto, and SIXTH STREET SPECIALTY LENDING,
INC., a Delaware corporation (“Sixth Street”), as administrative agent for the Lenders (in such capacity, together
with its successors and assigns in such capacity, the “Administrative Agent”).

WHEREAS,
the Loan Parties have requested that the Administrative Agent and the Lenders amend certain terms and conditions of the Financing
Agreement; and

WHEREAS,
the Administrative Agent and the Lenders are willing to amend such terms and conditions of the Financing Agreement on the terms
and conditions set forth herein.

 

NOW
THEREFORE, in consideration of the premises and other good and valuable consideration, the receipt and sufficiency of which
are hereby acknowledged, the parties hereto hereby agree as follows:

1.       
Definitions. All terms used herein that
are defined in the Financing Agreement and not otherwise defined herein shall have the meanings assigned to them in the Financing
Agreement.

2.       
Amendments.

(a)
         New Definitions. Section 1.01 of the Financing Agreement is hereby
amended by adding the following definitions, in appropriate alphabetical order:

(i)                
““Amendment No. 7” means Amendment No. 7 to Financing Agreement, dated as of January 13, 2021, by and
among the Loan Parties, the Administrative Agent and the Lenders.”

(ii)                
““Amendment No. 7 Effective Date” means the “Amendment Effective Date” as set forth in Amendment
No. 7.”

(iii)                
““Cash Collateral Account” means that certain Deposit Account with Bank of America, N.A. identified by
account number 4451020473.”

(iv)                
““Specified Payables” means the aggregate amount of all trade payables aged in excess of 60 days past
the applicable invoice date and all book overdrafts, in each case as reasonably determined by Administrative Agent.”

    	 	 	 

    	 

    

 

(b)
         Existing Definitions. Section 1.01 of the Financing Agreement is hereby amended as follows:

(i)                
 The definition of Excluded Account is hereby
amended and restated to read as follows:

““Excluded
Account” means (i) Deposit Accounts and Securities Accounts the balance of which consists exclusively of (a) withheld
income Taxes and federal, state or local employment Taxes in such amounts as are required to be paid to the Internal Revenue Service
or state or local government agencies within the following two months with respect to employees of the Company or any of its Subsidiaries,
and (b) any payroll accounts, health care reimbursement accounts and employee benefits accounts, including any accounts containing
amounts required to be paid over to an employee benefit plan pursuant to DOL Reg. Sec. 2510.3-102 on behalf of or for the benefit
of employees of the Company or any of its Subsidiaries, (ii) all segregated Deposit Accounts constituting (and the balance of
which consists solely of funds set aside in connection with) tax accounts, fiduciary accounts and trust accounts and (iii) any
Deposit Accounts and Securities Accounts, amounts on deposit in which do not exceed $100,000 individually or $500,000 in the aggregate
at any one time, (iv) any Deposit Accounts that contain accounts receivable arising from any Governmental Payor where Administrative
Agent may not under applicable Law obtain a security interest in or lien on such Deposit Account receiving the proceeds of such
accounts receivable; provided, that amounts in such Deposit Account referred to in this subclause (iv) are automatically
transferred on each Business Day into a Deposit Account that is not an Excluded Account, (v) the Cash Collateral Account, or (vi)
the Deposit Account with Bank of America, N.A. identified by account number 4451288202.”

(ii)                
The definition of Permitted Indebtedness is hereby amended by deleting “and” at the end of clause (m), deleting the
“.” at the end of clause (n) and inserting a “;” in place thereof, and inserting a new clause (o) as follows:

“(o)Indebtedness
of the Loan Parties in respect of credit card programs in the ordinary course of business in an aggregate amount not to exceed
$200,000 at any time outstanding.”

(iii)           
The definition of Permitted Liens is hereby amended by deleting “and” at the end of clause (p), deleting the “.”
at the end of clause (q) and inserting a “;” in place thereof, and inserting a new clause (r) as follows:

“(r)Liens
on the Cash Collateral Account securing Permitted Indebtedness described under clause (o) of the definition thereof.”

(c)
          Section 5.1(a) (Cash Reports). Section 5.1(a) of the Financing Agreement
is hereby amended and restated in its entirety to read as follows:

“(a)Cash
Reports. Promptly, but in any event within 5 Business Days, after the end of each week commencing with the week ending January
15, 2021, a report (which report may consist of bank statements) of the current Cash and Cash Equivalent balances (including the
balances in each Deposit Account of each Loan Party) of the Company and its Subsidiaries, which report shall identify (i) unrestricted
(other than restrictions created by the Collateral Documents) and restricted Cash and Cash Equivalents and (ii) those accounts
that constitute Qualified Cash; provided, that at any time the current Cash and Cash Equivalent balances of the Company
and its Subsidiaries is less than (A) $75,000,000, the Company shall either (1) on each Business Day provide a report of at least 95% of the current
Cash and Cash Equivalent balances of the Company and its Subsidiaries (the “Specified Cash”), which report
shall identify unrestricted (other than restrictions created by the Collateral Documents) and restricted Cash and Cash Equivalents
(or, if greater, all Cash and Cash Equivalent balances required to satisfy the covenant set forth in Section 6.8) or (2)
provide Administrative Agent with electronic, read only access to such Deposit Accounts of the Company and its Subsidiaries which
contain the Specified Cash and (B) $60,000,000, the Company shall immediately notify Administrative Agent in writing of the current
Cash and Cash Equivalent balances (including the balances in each Deposit Account of each Loan Party) of the Company and its Subsidiaries.”

    	 	 	 

    	 

    

(d)
         Section
6.8(a) (Minimum Qualified Cash). Section 6.8(a) of the Financing Agreement is hereby amended and restated in its entirety
to read as follows:

“(a)Minimum
Qualified Cash. At all times, Borrower shall not permit Qualified Cash to be less than $60,000,000 minus the Specified
Payables.”

(e)
         Section 6.8(b) (Minimum Revenue). Section 6.8(b) of the Financing
Agreement is hereby amended by amending the table set forth therein for the Fiscal Quarters ending March 31, 2021 and June 30,
2021 such that the minimum Product Revenue for the Fiscal Quarter ending (i) March 31, 2021 shall be $18,000,000 and (ii) June
30, 2021 shall be $22,000,000.

3.       
Waiver.

(a)
         Pursuant to the request of the Loan Parties and in reliance upon the representations
and warranties of the Loan Parties described herein, Administrative Agent and the Lenders hereby waive any Event of Default under
Section 8.1(c) of the Financing Agreement arising out of the Loan Parties’ failure to comply with Section 6.16 of the Financing
Agreement solely as a result of the failure of the Loan Parties to cause the Cash Collateral Account to be subject to a Control
Agreement (the “Specified Event of Default”).

(b)
         The waiver in this Section 3 shall be effective only in this specific instance
and for the specific purpose set forth herein and does not allow for any other or further departure from the terms and conditions
of the Financing Agreement or any other Loan Document, which terms and conditions shall continue in full force and effect.

4.       
Conditions to Effectiveness. This Amendment
shall become effective only upon satisfaction in full, in a manner satisfactory to the Administrative Agent, of the following
conditions precedent (the first date upon which all such conditions shall have been satisfied being hereinafter referred to as
the “Amendment Effective Date”):

(a)
         Payment of Fees, Etc. The Borrowers shall have paid on or before the Amendment
Effective Date (i) an amendment fee equal to $5,000,000, which fee shall be fully earned, due and payable to Administrative Agent
on the Amendment Effective Date, and (ii) all fees, costs, expenses and taxes then payable, if any, pursuant to Section
2.7 or 10.2 of the Financing Agreement.

    	 	 	 

    	 

    

 

(b)
         Representations and Warranties. The
representations and warranties contained in this Amendment and in Article IV
of the Financing Agreement and in each other Loan Document shall be true and correct in all material respects (except that
such materiality qualifier shall not be applicable to any representations or warranties that already are qualified or modified
as to “materiality” or “Material Adverse Effect” in the text thereof, which representations and warranties
shall be true and correct in all respects subject to such qualification) on and as the Amendment Effective Date to the same extent
as though made on and as of that date, except to the extent such representations and warranties specifically relate to an earlier
date, in which case such representations and warranties shall have been true and correct in all material respects (except that
such materiality qualifier shall not be applicable to any representations or warranties that already are qualified or modified
as to “materiality” or “Material Adverse Effect” in the text thereof, which representations and warranties
shall be true and correct in all respects subject to such qualification) on and as of such earlier date.

(c)
         No Default; Event of Default. No Default or Event of Default (other than
the Specified Event of Default) shall have occurred and be continuing on the Amendment Effective Date or result from this Amendment
becoming effective in accordance with its terms.

(d)
         Delivery of Documents. The Administrative Agent shall have received on
or before the Amendment Effective Date:

(i)                
this Amendment, duly executed by the Loan Parties, the Administrative Agent and the Lenders; and

(ii)               
an amendment to each Warrant to Purchase Common Stock dated August 5, 2020 issued by the Borrower to Sixth Street, Redwood IV
Finance 1, LLC and TAO Finance 1, LLC, in each case in form and substance satisfactory to the Administrative Agent and duly executed
by the Borrower.

(e)
         Material Adverse Effect. The Administrative Agent shall have determined,
in its reasonable judgment, that no event or development shall have occurred since December 31, 2019, which could reasonably be
expected to have a Material Adverse Effect.

(f)
          Liens; Priority. The Administrative Agent shall be satisfied that
the Administrative Agent has been granted, and holds, for the benefit of the Administrative Agent and the Lenders, a perfected,
first priority Lien on and security interest in all of the Collateral, subject only to Permitted Liens, to the extent such Liens
and security interests are required pursuant to the Loan Documents to be granted or perfected on or before the Amendment Effective
Date.

(g)
         Approvals. All consents, authorizations and approvals of, and filings
and registrations with, and all other actions in respect of, any Governmental Authority or other Person required in connection
with any Loan Document or the transactions contemplated thereby or the conduct of the Loan Parties’ business shall have
been obtained or made and shall be in full force and effect. There shall exist no claim, action, suit, investigation, litigation
or proceeding (including, without limitation, shareholder or derivative litigation) pending or, to the knowledge
of any Loan Party, threatened in any court or before any arbitrator or Governmental Authority which (i) relates to the Loan
Documents or the transactions contemplated thereby or (ii) could reasonably be expected to have a Material Adverse Effect.

    	 	 	 

    	 

    

5.       
Conditions Subsequent to Effectiveness.
As an accommodation to the Loan Parties, Administrative Agent and the Lenders have agreed to execute this Amendment notwithstanding
the failure by the Loan Parties to satisfy the conditions set forth below on or before the Amendment Effective Date. In consideration
of such accommodation, the Loan Parties agree that, in addition to all other terms, conditions and provisions set forth herein
and in the Financing Agreement and the other Loan Documents, including, without limitation, those conditions set forth in Section
4 hereof, the Loan Parties shall satisfy each of the conditions subsequent set forth below on or before the date applicable thereto
(it being understood that (a) the failure by the Loan Parties to perform or cause to be performed any such condition subsequent
on or before the date applicable thereto shall constitute an Event of Default and (b) to the extent that the existence of any
such condition subsequent would otherwise cause any representation, warranty or covenant in this Amendment, the Financing Agreement
or any other Loan Document to be breached, the Required Lenders hereby waive such breach for the period from the Amendment Effective
Date until the date on which such condition subsequent is required to be fulfilled pursuant to this Section 5):

(a)              
On or prior to the date that is 30 days following the Amendment Effective Date (or such later date as agreed to in writing by
Administrative Agent in its sole discretion), the Loan Parties shall deliver to Administrative Agent (x) Control Agreements for
(i) each Deposit Account identified on Exhibit A hereto and (ii) any other Deposit Account with respect to which a Control
Agreement is required to be delivered under the Loan Documents, in each case duly executed by, in addition to the applicable Loan
Party, the applicable financial institution, (y) evidence that the Deposit Account identified by account number 898049551890 has
been closed; and

(b)              
On or prior to the date that is 5 Business Days following the Amendment Effective Date (or such later date as agreed to in writing
by Administrative Agent in its sole discretion), the Loan Parties shall deliver to Administrative Agent Collateral Assignments
for Security in respect of the trademarks, patents and patent applications identified on Exhibit B hereto.

6.       
Continued Effectiveness of the Financing Agreement
and Other Loan Documents. Each Loan Party hereby (a) acknowledges and consents to this Amendment, (b) confirms and agrees
that the Financing Agreement and each other Loan Document to which it is a party is, and shall continue to be, in full force and
effect and is hereby ratified and confirmed in all respects, except that on and after the Amendment Effective Date, all references
in any such Loan Document to “the Financing Agreement”, the “Agreement”, “thereto”, “thereof”,
“thereunder” or words of like import referring to the Financing Agreement shall mean the Financing Agreement as amended
by this Amendment, and (c) confirms and agrees that, to the extent that any such Loan Document purports to assign or pledge
to the Administrative Agent, for the benefit of the Administrative Agent and the Lenders, or to grant to the Administrative Agent,
for the benefit of the Administrative Agent and the Lenders, a security interest in or Lien on any Collateral as security for
the Obligations of the Loan Parties from time to time existing in respect
of the Financing Agreement (as amended hereby) and the other Loan Documents, such pledge, assignment and/or grant of the security
interest or Lien is hereby ratified and confirmed in all respects. This Amendment does not and shall not affect any of the obligations
of the Loan Parties, other than as expressly provided herein, including, without limitation, the Loan Parties’ obligations
to repay the Loans in accordance with the terms of Financing Agreement or the obligations of the Loan Parties under any Loan Document
to which they are a party, all of which obligations shall remain in full force and effect. Except as expressly provided herein,
the execution, delivery and effectiveness of this Amendment shall not operate as a waiver of any right, power or remedy of Administrative
Agent or any Lender under the Financing Agreement or any other Loan Document nor constitute a waiver of any provision of the Financing
Agreement or any other Loan Document.

    	 	 	 

    	 

    

7.       
No Novation. Nothing herein contained
shall be construed as a substitution or novation of the Obligations outstanding under the Financing Agreement or instruments securing
the same, which shall remain in full force and effect, except as modified hereby.

8.       
No Representations by Administrative Agent
or Lenders. Each Loan Party hereby acknowledges that it has not relied on any representation, written or oral, express or
implied, by Administrative Agent or any Lender, other than those expressly contained herein, in entering into this Amendment.

9.       
Release. Each Loan Party hereby acknowledges
and agrees that: (a) neither it nor any of its Subsidiaries has any claim or cause of action against Administrative Agent or any
Lender (or any of the directors, officers, employees, agents, attorneys or consultants of any of the foregoing) and (b) the Administrative
Agent and the Lenders have heretofore properly performed and satisfied in a timely manner all of their obligations to the Loan
Parties, and all of their Subsidiaries and Affiliates. Notwithstanding the foregoing, the Administrative Agent and the Lenders
wish (and the Loan Parties agree) to eliminate any possibility that any past conditions, acts, omissions, events or circumstances
would impair or otherwise adversely affect any of their rights, interests, security and/or remedies. Accordingly, for and in consideration
of the agreements contained in this Amendment and other good and valuable consideration, each Loan Party (for itself and its Subsidiaries
and Affiliates and the successors, assigns, heirs and representatives of each of the foregoing) (collectively, the “Releasors”)
does hereby fully, finally, unconditionally and irrevocably release, waive and forever discharge the Administrative Agent and
the Lenders, together with their respective Affiliates and Related Funds, and each of the directors, officers, employees, agents,
attorneys and consultants of each of the foregoing (collectively, the “Released Parties”), from any and all
debts, claims, allegations, obligations, damages, costs, attorneys’ fees, suits, demands, liabilities, actions, proceedings
and causes of action, in each case, whether known or unknown, contingent or fixed, direct or indirect, and of whatever nature
or description, and whether in law or in equity, under contract, tort, statute or otherwise, which any Releasor has heretofore
had or now or hereafter can, shall or may have against any Released Party by reason of any act, omission or thing whatsoever done
or omitted to be done, in each case, on or prior to the Amendment Effective Date directly arising out of, connected with or related
to this Amendment, the Financing Agreement or any other Loan Document, or any act, event or transaction related or attendant thereto,
or the agreements of Administrative Agent or any Lender contained therein, or the possession, use, operation or control of any
of the assets of any Loan Party, or the making of any Loans or other advances, or the
management of such Loans or other advances or the Collateral. Each Loan Party represents and warrants that it has no knowledge
of any claim by any Releasor against any Released Party or of any facts or acts or omissions of any Released Party which on the
date hereof would be the basis of a claim by any Releasor against any Released Party which would not be released hereby.

    	 	 	 

    	 

    

10.
        Further
Assurances. The Loan Parties shall execute any and all further documents, agreements and instruments, and take all further
actions, as may be required under applicable law or as Administrative Agent may reasonably request, in order to effect the purposes
of this Amendment.

11.
        Miscellaneous.

(a)
         This Amendment may be executed in any number of counterparts and by different
parties hereto in separate counterparts, each of which shall be deemed to be an original but all of which taken together shall
constitute one and the same agreement. Delivery of an executed counterpart of this Amendment by facsimile or electronic mail shall
be equally effective as delivery of an original executed counterpart of this Amendment.

(b)
         Section and paragraph headings herein are included for convenience of reference
only and shall not constitute a part of this Amendment for any other purpose.

(c)
         This Amendment shall be governed by, and construed in accordance with, the laws
of the State of New York.

(d)
         Each Loan Party hereby acknowledges and agrees that this Amendment constitutes
a “Loan Document” under the Financing Agreement. Accordingly, it shall be an immediate Event of Default under the
Financing Agreement if (i) any representation or warranty made by any Loan Party under or in connection with this Amendment shall
have been incorrect in any respect when made or deemed made, or (ii) any Loan Party shall fail to perform or observe any term,
covenant or agreement contained in this Amendment.

(e)
         Any provision of this Amendment that is prohibited or unenforceable in any jurisdiction
shall, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the
remaining portions hereof or affecting the validity or enforceability of such provision in any other jurisdiction.

 

[Remainder
of page intentionally left blank.]

 

 

 

    	 	 	 

    	 

    

 

IN
WITNESS WHEREOF, the parties hereto have caused this Amendment to be executed and delivered as of the date set forth on the first
page hereof. 

	 	BORROWER:
	 	 
	 	THERAPEUTICSMD, INC.
	 	 
	 	By:	/s/ James C. D’Arecca	 
	 	Name:	
    James C. D’Arecca
	 	Title:	Chief Financial Officer
	 	 
	 	 
	 	GUARANTORS:
	 	 
	 	VITAMEDMD,
        LLC
	 	 
	 	By:	/s/ James C. D’Arecca	 
	 	Name:	James C. D’Arecca
	 	Title:	Chief Financial Officer
	 	 
	 	 
	 	 BOCAGREENMD, INC.
	 	 
	 	By:	/s/ James C. D’Arecca	 
	 	Name:	James C. D’Arecca
	 	Title:	Chief Financial Officer
	 	 
	 	 
	 	VITACARE PRESCRIPTION SERVICES, INC.
	 	 
	 	By:	/s/ John C.K. Milligan, IV	 
	 	Name:	
        John C.K. Milligan, IV
	 	Title:	President

 

    	 	 	 

    	 

    

 

	 	SIXTH
STREET SPECIALTY LENDING, INC., 

as Administrative Agent and Lender

 

		By:	/s/ Joshua Easterly	 
	 	 	Name:
                                         Joshua Easterly
	 	 	Title:
                                         Chief Executive Officer

 

 

	 	TOP
    IV TALENTS, LLC, as Lender

 

		By:	/s/ Joshua Peck 	 
	 	 	Name:
                                         Joshua Peck
	 	 	Title:
                                         Vice President

 

 

	 	TAO TALENTS, LLC, as Lender

 

		By:	/s/ Joshua Peck 	 
	 	 	Name:
                                         Joshua Peck
	 	 	Title:
                                         Vice President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00323-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00323-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00323-of-00352.parquet"}]]